Healthcare Wrap: Imugene Soars, Vitasora Rallies as Biotech Price Swings Persist

Imugene (ASX:IMU) topped the healthcare board with a 36.84% gain after reporting an 81% response rate for azer-cel in a group of blood cancer patients who had not previously received CAR T treatment. Investors cared because response rates are a simple readout: if more patients improve, the drug looks more valuable. Vitasora (ASX:VHL) climbed 27.27% after launching its own electronic medical record system and saying software costs should fall by more than 90%, while patient enrolments more than doubled in April. Adherium (ASX:ADR) added 25.00% after proposing a 1-for-100 share consolidation, a move companies use to reduce very low share counts and try to make trading look cleaner on screen.

Biotech wins were real, but price reactions were uneven

Island Pharmaceuticals (ASX:ILA) rose 24.29% across two updates that strengthened its US biodefence push for Galidesivir. The company hired a former BioCryst executive with direct knowledge of the drug and added another adviser with deep government links. That mattered because Island needs US trial access and, later, government buyers. Patrys (ASX:PAB) gained 19.35% after naming the site and contract research group for its Phase 1A trial. In plain English, it locked in the people needed to run first-in-human testing. On the other side, several companies released encouraging science and still fell. Argenica (ASX:AGN) slid 13.79% even after clearing an FDA-requested safety test for its stroke drug. 4DMedical (ASX:4DX) dropped 13.19% despite a peer-reviewed study that showed its lung imaging tool could improve surgery selection. Amplia Therapeutics (ASX:ATX) lost 13.33% after launching a new pancreatic cancer study. The likely issue was timing. These updates improved the story, but they did not bring near-term sales, and smaller biotech investors often want the next clear result before paying up.

Software and imaging names kept landing real customers

Pro Medicus (ASX:PME) rose 4.78% after winning a seven-year, A$90 million cloud imaging contract with Beth Israel Lahey Health in the US. A contract of that size gives investors something simple to work with: known customers, known time period and a clear install target. Mach7 Technologies (ASX:M7T) gained 12.07% on a five-year A$1.7 million subscription deal with AMRADNET, while Alcidion (ASX:ALC) rose 11.11% after buying Telstra Health's Kyra patient flow products. That deal adds 33 customers and mostly recurring revenue, which means revenue that repeats rather than relying on one-off sales. IMEXHS (ASX:IME) also showed the appeal of healthcare software. The company beat its full-year revenue and profit targets, helped by AI tools that automate radiology work. Yet the stock still finished the week down 2.70%. The move looked softer once trading resumed, with shares up 1.41% from the re-open price. That suggests early losses eased as investors read the result in more detail. Lumos Diagnostics (ASX:LDX) showed a similar pattern in reverse. It reported strong US reimbursement for FebriDx, but the stock ended flat for the week and was down 3.85% from the re-open price, which points to early support fading.

Takeovers, hospital deals and earnings gave the sector a steadier base

SDI Limited (ASX:SDI) advanced 8.43% as its A$1.40 a share acquisition moved through court and booklet stages. Investors tend to focus on the spread between the trading price and the bid price in cash deals, plus the chance of approvals failing. This one still needs shareholder, court and regulatory sign-off, but board support and a large premium kept interest firm. EBR Systems (ASX:EBR) signed purchasing agreements covering 69 Advocate Health hospitals and 66 CHRISTUS Health hospitals, yet the stock fell 13.27%. The market may have wanted revenue timing, not just access. Hospital purchasing deals can open doors, but sales still take time. AFT Pharmaceuticals (ASX:AFP) was one of the cleanest earnings stories. Revenue rose 22% to NZ$254.7 million and operating profit hit a record NZ$24.4 million, beating guidance. The shares added 11.72%. Oceania Healthcare (ASX:OCA) reported record earnings, stronger sales and lower debt, but the stock fell 7.96%. Investors may have focused on the lack of a dividend and the fact free cash flow was still negative, even though it improved. Little Green Pharma (ASX:LGP) slipped 2.06% after revenue grew 15.3%, because inventory write-downs pushed it to a loss.

Capital raising and trading gaps still shaped smaller names

TruScreen (ASX:TRU) fell 7.14% after launching a NZ$2.9 million capital raising, despite reporting 42% product sales growth. New shares can help fund expansion, but they also increase the share count, which can pressure the price. PainChek (ASX:PCK) handled funding better, rising 3.70% after securing A$5.5 million in convertible notes to back its US rollout. Vectus Biosystems (ASX:VBS) dipped 4.17% after a smaller placement to support its fibrosis trial. Some gap moves were worth noting. BCAL Diagnostics (ASX:BDX) closed the week down 10.84%, but from the re-open price the stock moved only 1.33% lower. That points to an air pocket: the price reset lower, then mostly stabilised. Alterity Therapeutics (ASX:ATH) finished unchanged for the week, yet rose 11.11% from its re-open level after strong Multiple System Atrophy trial data. That means buyers stepped in after trading resumed and kept buying. Pro Medicus held most of its weekly gain even though it was almost flat from the re-open price, which suggests the earlier jump largely stuck rather than disappearing.